Acekaitiz Capsule

NULL is a capsule containing Acebrophylline, a derivative of theophylline that acts as both a bronchodilator and a mucolytic agent. It is prescribed for the long-term treatment and maintenance of chronic obstructive pulmonary disease (COPD), bronchial asthma, and chronic bronchitis. Its dual action helps open the airways by relaxing the bronchial muscles while simultaneously thinning and clearing thick mucus (sputum), significantly easing the effort of breathing and reducing cough frequency. NULL provides symptomatic relief and improves lung function for patients with airflow limitation and excessive mucus production

NULL contains Acebrophylline, a potent molecule that delivers two distinct pharmacological benefits crucial for managing chronic respiratory illnesses. It is formed by the chemical combination of ambroxol (a mucolytic) and theophylline-7-acetic acid (a bronchodilator).

The bronchodilator component works by relaxing the smooth muscles surrounding the bronchial tubes. This widening of the airways, achieved primarily through phosphodiesterase inhibition, reduces resistance to airflow, which is critical in conditions like asthma and COPD.

The mucolytic action is due to the release of Ambroxol. Ambroxol promotes the breakdown of acidic mucopolysaccharide fibres, leading to decreased mucus viscosity and enhanced ciliary activity. This dual function not only addresses bronchoconstriction but also manages the hypersecretion of thick mucus, improving mucociliary clearance and reducing the frequency of infection and respiratory distress. This comprehensive approach makes NULL a valuable maintenance therapy.

NULL is indicated for the following chronic respiratory conditions:

Chronic Obstructive Pulmonary Disease (COPD):

Used as maintenance therapy to improve breathing and reduce exacerbations.

Bronchial Asthma:

Prescribed to control airway symptoms, especially when associated with excessive sputum production.

Chronic Bronchitis:

Used to manage chronic cough, reduce mucus viscosity, and facilitate expectoration.

The combination of actions in NULL provides specific therapeutic advantages for chronic respiratory patients:

Dual-Action Treatment:

It is one of the few medications that simultaneously addresses both major components of COPD and asthma: airway narrowing (bronchospasm) and mucus obstruction (mucus hypersecretion).

Improved Airflow and Clearance:

By acting as a bronchodilator, it widens the air passages. As a mucolytic, it liquefies tenacious sputum, making it easier to cough up. This synergy leads to a measurable improvement in pulmonary function test results.

Reduced Frequency of Cough and Dyspnea:

Patients experience a significant reduction in the severity and frequency of coughing spells and breathlessness (dyspnea) due to clearer airways.

Anti-Inflammatory Properties (Minor):

Acebrophylline also exhibits mild anti-inflammatory effects in the airways, contributing to long-term symptom stability and reduced airway hyper-reactivity.

While generally well-tolerated at the recommended dose, NULL can cause side effects primarily related to its theophylline-like nature.

Common Side Effects

These are generally mild and may subside with continued use:

• Nausea, vomiting, or stomach upset (epigastric discomfort)
• Heartburn (gastroesophageal reflux)
• Headache or dizziness
• Mild tremors or palpitations (fast or irregular heartbeat)

Critical Side Effects

Seek medical help immediately if you notice:

• Severe Allergic Reaction: Rash, hives, swelling of the face, lips, tongue, or difficulty breathing.
• Severe Cardiovascular Events: Marked increase in heart rate (tachycardia) or irregular heart rhythm (arrhythmia), especially in patients with pre-existing heart conditions.
• Central Nervous System Excitation: Symptoms such as confusion, restlessness, or seizures (rare, and usually associated with very high serum levels).
• Gastrointestinal Bleeding: Black, tarry stools, or vomiting blood.

Always take NULL exactly as prescribed by your doctor.

• Administration: Swallow the capsule whole with a glass of water. Do not open, crush, or chew the capsule.
• Timing: The typical dosing schedule is one capsule once or twice daily, as advised by your physician. It should be taken at regular intervals.
• Food: NULL is usually recommended to be taken after meals to minimise gastrointestinal irritation, which is a common effect of the theophylline component.
• Duration: This is a long-term maintenance drug. Do not stop taking it even if your symptoms improve unless directed by your doctor.

NULL provides two essential actions for the management of chronic airway disease:

1. Bronchodilation: Acebrophylline acts as a bronchodilator primarily by inhibiting the enzyme phosphodiesterase (PDE). PDE inhibition leads to an accumulation of cyclic adenosine monophosphate (cAMP) in smooth muscle cells, causing the relaxation of the bronchial smooth muscles and the widening of the airways.
2. Mucolysis: The Ambroxol moiety facilitates mucolysis by activating the serous glands of the respiratory tract. It promotes the production of a less viscous, more watery mucus, while simultaneously breaking down the complex structures of the thick, sticky sputum. This reduction in viscosity and enhanced ciliary motility improves the efficiency of coughing and clearing the airways. The synergistic effect of opening the airways and clearing the obstruction is paramount to improving lung mechanics.

• Take After Food: Always take this capsule after a meal to minimise the chances of stomach upset, heartburn, or nausea.
• Report Palpitations: If you notice a persistent or severe increase in heart rate or palpitations, report this to your doctor immediately, as the dose may need adjustment.
• Consistency: Take the medication regularly every day for maintenance therapy, even on days when breathing feels good.
• Hydrate Well: Drink plenty of water throughout the day to support the mucolytic action and help clear lung secretions.
• Interactions: Inform your doctor about all medications, especially antibiotics (like Ciprofloxacin) and anti-ulcer drugs (like Cimetidine), as they can significantly increase Acebrophylline levels.

• Store NULL at controlled room temperature, typically between 20 °C and 25 °C (68 °F and 77 °F).
• Keep the capsules in their original packaging, protected from moisture and direct sunlight.
• Do not use the capsules past the expiry date printed on the packaging.
• Keep this and all medications out of the reach of children and pets.

• High-Fat Meals: Taking the capsule immediately after a very high-fat meal may slightly increase the time it takes for the drug to be absorbed. This is generally not clinically significant, but should be considered if symptoms worsen after large meals.
• Caffeine: High intake of caffeine, a xanthine derivative like Acebrophylline, can enhance the side effects of the medication (e.g., tremors, palpitations, insomnia) and should be moderated.

The co-administration of NULL with certain drugs can significantly affect its metabolism and safety profile.

Interactions that Increase Acebrophylline Levels (Risk of Toxicity)

• Antibiotics (e.g., Ciprofloxacin, Erythromycin): These drugs inhibit the liver enzymes responsible for metabolising Acebrophylline, leading to dangerously high serum concentrations and toxicity (nausea, vomiting, seizures). The dose of Acebrophylline must be reduced.

• Cimetidine: This anti-ulcer medication significantly reduces the clearance of Acebrophylline, requiring careful monitoring.

• Beta-Blockers (Non-Selective): May counteract the bronchodilator effect of Acebrophylline.

Interactions that Decrease Acebrophylline Levels (Reduced Efficacy)

• Anticonvulsants (e.g., Phenytoin, Carbamazepine): These drugs induce liver enzymes, increasing the breakdown of Acebrophylline and potentially reducing its therapeutic effect.

• Smoking: Tobacco smoke induces liver enzymes, requiring higher dosing of Acebrophylline in chronic smokers to maintain efficacy.

Caution is required for patients with:

• Cardiovascular Disease: Contraindicated in patients with acute myocardial infarction (heart attack) and severe, unstable angina. Use with caution in patients with uncontrolled arrhythmias.
• Severe Liver Disease (Hepatic Impairment): Clearance is significantly delayed, leading to toxic levels of the drug. Dose reduction or avoidance is necessary.
• Severe Kidney Disease (Renal Impairment): Excretion of the drug is impaired, requiring dose adjustment.
• Active Peptic Ulcer Disease: The theophylline component can increase gastric acid secretion and should be used with caution in patients with active ulcers.

The dose is determined based on the severity of the respiratory condition and patient tolerance.

• Standard Adult Dose: One capsule of 100mg, typically administered once or twice daily (e.g., morning and evening).
• Maintenance: The 100mg strength is standard for maintenance therapy in stable patients.
• Maximum Dose: The total daily dose should not exceed 200mg (two 100mg capsules) unless specifically advised by a physician for a short period and under close monitoring.

An overdose of NULL can lead to symptoms primarily associated with theophylline toxicity. These include severe nausea, persistent vomiting, severe headache, restlessness, marked palpitations or tachycardia (fast heart rate), and, in severe cases, cardiac arrhythmias, confusion, and generalised seizures.

If overdose is suspected, seek immediate emergency medical attention. Treatment is supportive and aimed at stopping further absorption (e.g., activated charcoal) and managing severe symptoms, particularly cardiac arrhythmias and seizures.

If you miss a dose of NULL, take it as soon as you remember. If it is already time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the missed one, as this increases the risk of side effects like nausea and palpitations.